RENOPHARM Ltd
uses proprietary, patent pending approach in the synthesis of Nitric Oxide (NO)
donors, based on NO attachment to natural chemical groups. These chemical
groups are part of physiological compounds or their natural metabolites. This
novel compound form prevents the formation of drug tolerance induced by the
current NO donor repeated treatment. The preliminary in vitro and in vivo test
results demonstrate their higher effectiveness in comparison to the current
medical treatment with Nitroglycerin drugs.
NO is the answer
INVESTOR RELATIONS
WHY RENOPHARM
Renopharm has received a US patent for its Novel Nitric Oxide Technology. today
announced it has received an Issue Notification, informing that US Patent
Application
Synthesize
Nitric Oxide (NO) donor compounds. Screen in-vitro & in-vivo for efficacy
& no-tolerance induction. Select lead compounds for tests in preparation
for Phase I of clinical trials.
Renopharm has received a notice of allowance of its US patent application
covering its lead compound Pet-8, for treating cardiovascular disorders and
related medical conditions.
Synthesize
Nitric Oxide (NO) donor compounds. Screen in-vitro & in-vivo for efficacy
& no-tolerance induction. Select lead compounds for tests in preparation
for Phase I of clinical trials.
Renopharm
is synthe-sizing a pipeline of proprietary, patent pending novel Nitric Oxide
(NO) donor compounds.